Clinical Trials on EGFR-mutant Non-small Cell Lung Cancer

Total 7935 results

Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

EGFR-mutant Non-Small Cell Lung Cancer

China
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
J Ints Bio

Recruiting

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

EGFR Mutant Advanced Non-small Cell Lung Cancer

Korea, Republic of, United States, Thailand
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Non-small Cell Lung Cancer | EGFR-mutant Lung Cancers

United States
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
University of Sydney
AstraZeneca; Australasian Lung Cancer Trials Group

Active, not recruiting

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE)

EGFR Mutant Advanced Non Small Cell Lung Cancer

Taiwan, Australia
Therapex Co., Ltd

Not yet recruiting

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Carcinoma, Non-Small-Cell Lung | EGFR Mutant Advanced Non-Small Cell Lung Cancer
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Fudan University

Unknown

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (APPEAL)

Lung Cancer, Non-small Cell | EGFR Gene Mutation | EGFR T790M

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
GenoSaber
Sun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...

Unknown

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Non Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MD

Recruiting

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM)

NSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditions

Italy
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
Beijing Chest Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

HER2 Mutant Non-small Cell Lung Cancer
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
University Hospital, Angers
University Hospital, Rouen; Central Hospital, Nancy, France; University Hospital... and other collaborators

Unknown

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient (FLT-THERA)

Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent | No EGFR Activating Mutation

France
National University Hospital, Singapore

Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

Non Small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Singapore
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
Massachusetts General Hospital
American Lung Association

Recruiting

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Carcinoma, Non-Small-Cell Lung | Nonsmall Cell Lung Cancer | Palliative Care | Survivorship | Targeted Therapy | Stage IV Non-small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer | ALK-positive Non-small Cell Lung Cancer

United States
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
Fujian Cancer Hospital

Not yet recruiting

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

EGFR Positive Non-small Cell Lung Cancer

China
National Cancer Center, Korea
Roche Korea co.,Ltd.

Active, not recruiting

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) (AvaTa)

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (DL-05)

HER2-mutant Non-Small Cell Lung Cancer

China
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
Juntendo University
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Non-squamous Non-small-cell Lung Cancer | EGFR Activating Mutation

Japan
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer

China
Korea University Guro Hospital
Chong Kun Dang Pharmaceutical Corp.

Active, not recruiting

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Massachusetts General Hospital
Boehringer Ingelheim; University of Texas

Completed

Understanding Mechanisms of Acquired Resistance to BIBW2992

Non-small Cell Lung Cancer | EGFR Mutations

United States
Yuankai Shi

Unknown

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China

Clinical Trials on EGFR-mutant Non-small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations